While these findings raise concerns that targeting ACC may aggravate atherogenic dyslipidemia, co-administration of PF-05221304 with a diacylglycerol acyltransferase 2 inhibitor (PF-06865571), reduced liver fat assessed by MRI-PDFF and mitigated the increase in circulating triglycerides in patients with NAFLD (347). Here, ACACA is linked to metabolic dysfunction-associated steatotic liver disease.